BACKGROUND: Low bone mineral density (BMD) is common among patients infected with human immunodeficiency virus (HIV) and present in higher rates in black subjects. This study assessed vitamin D levels in HIV cases versus noninfected matched controls to determine if deficiency was associated with BMD and HIV clinical outcomes. METHODS: In total, 271 military beneficiaries with HIV underwent dual energy x-ray absorptiometry (DEXA) screening in 2001-2. Serum 25OH-vitamin D levels were determined using stored serum from the time of DEXA and 6-18 months prior. Two non-HIV-infected controls for each active duty case (n = 205) were matched on age, sex, race, zip code, and season using the Department of Defense Serum Repository (DoDSR). Vitamin D levels <20 ng/mL were considered deficient. HIV-related factors and clinical outcomes were assessed using data collected in the DoD HIV Natural History study. RESULTS: In total, 165 of 205 (80.5%) active duty HIV cases had 2 matched controls available. HIV cases had greater odds of for vitamin D deficiency (VDD) compared with controls (demographics adjusted paired data odds ratio [OR], 1.46, 95% confidence interval [CI], .87-2.45), but this was not statistically significant. Blacks were disproportionately deficient (P <.001) but not relative to HIV status or BMD. Low BMD was associated with typical risk factors (low body mass index and exercise levels, alcohol use); given limited available data the relationship between tenofovir exposure and VDD or low BMD could not be determined. Analysis of HIV-specific factors and outcomes such as exposure to antiretrovirals, HIV progression, hospitalizations, and death revealed no significant associations with vitamin D levels. CONCLUSIONS: VDD was highly prevalent in black HIV- infected persons but did not explain the observed racial disparity in BMD. Vitamin D deficiency was not more common among HIV- infected persons, nor did it seem associated with HIV- related factors/clinical outcomes.
BACKGROUND: Low bone mineral density (BMD) is common among patients infected with human immunodeficiency virus (HIV) and present in higher rates in black subjects. This study assessed vitamin D levels in HIV cases versus noninfected matched controls to determine if deficiency was associated with BMD and HIV clinical outcomes. METHODS: In total, 271 military beneficiaries with HIV underwent dual energy x-ray absorptiometry (DEXA) screening in 2001-2. Serum 25OH-vitamin D levels were determined using stored serum from the time of DEXA and 6-18 months prior. Two non-HIV-infected controls for each active duty case (n = 205) were matched on age, sex, race, zip code, and season using the Department of Defense Serum Repository (DoDSR). Vitamin D levels <20 ng/mL were considered deficient. HIV-related factors and clinical outcomes were assessed using data collected in the DoD HIV Natural History study. RESULTS: In total, 165 of 205 (80.5%) active duty HIV cases had 2 matched controls available. HIV cases had greater odds of for vitamin D deficiency (VDD) compared with controls (demographics adjusted paired data odds ratio [OR], 1.46, 95% confidence interval [CI], .87-2.45), but this was not statistically significant. Blacks were disproportionately deficient (P <.001) but not relative to HIV status or BMD. Low BMD was associated with typical risk factors (low body mass index and exercise levels, alcohol use); given limited available data the relationship between tenofovir exposure and VDD or low BMD could not be determined. Analysis of HIV-specific factors and outcomes such as exposure to antiretrovirals, HIV progression, hospitalizations, and death revealed no significant associations with vitamin D levels. CONCLUSIONS: VDD was highly prevalent in black HIV- infectedpersons but did not explain the observed racial disparity in BMD. Vitamin D deficiency was not more common among HIV- infectedpersons, nor did it seem associated with HIV- related factors/clinical outcomes.
Authors: Christine N Dao; Pragna Patel; E Turner Overton; Frank Rhame; Sherri L Pals; Christopher Johnson; Timothy Bush; John T Brooks Journal: Clin Infect Dis Date: 2011-02-01 Impact factor: 9.079
Authors: Brenda Ormesher; Sandeep Dhaliwal; Eric Nylen; Cynthia Gibert; Christina Go; Richard Amdur; Debra Benator Journal: AIDS Date: 2011-06-01 Impact factor: 4.177
Authors: Giordano Madeddu; A Spanu; P Solinas; G M Calia; C Lovigu; F Chessa; M Mannazzu; A Falchi; M S Mura; Giuseppe Madeddu Journal: Q J Nucl Med Mol Imaging Date: 2004-03 Impact factor: 2.346
Authors: Amy C Weintrob; Greg A Grandits; Brian K Agan; Anuradha Ganesan; Michael L Landrum; Nancy F Crum-Cianflone; Erica N Johnson; Claudia E Ordóñez; Glenn W Wortmann; Vincent C Marconi Journal: J Acquir Immune Defic Syndr Date: 2009-12 Impact factor: 3.731
Authors: C Poiana; C Capatina; Anca Streinu Cercel; O Sandulescu; A Streinu Cercel Journal: Acta Endocrinol (Buchar) Date: 2019 Jan-Mar Impact factor: 0.877
Authors: Christopher L Perdue; Angelia A Eick Cost; Mark V Rubertone; Luther E Lindler; Sharon L Ludwig Journal: PLoS One Date: 2015-02-27 Impact factor: 3.240
Authors: Samuel Mwango; Janet Carboo; Christa Ellis; Marike Cockeran; Carina M C Mels; Herculina S Kruger Journal: South Afr J HIV Med Date: 2021-09-30 Impact factor: 2.744